Last reviewed · How we verify
forodesine HCl
At a glance
| Generic name | forodesine HCl |
|---|---|
| Sponsor | BioCryst Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients (PHASE1, PHASE2)
- Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies (PHASE1)
- Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma (PHASE1)
- BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma (PHASE1, PHASE2)
- BCX-1777 in Treating Patients With Refractory Cancer (PHASE1)
- Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) (PHASE2)
- Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens (PHASE2)
- Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- forodesine HCl CI brief — competitive landscape report
- forodesine HCl updates RSS · CI watch RSS
- BioCryst Pharmaceuticals portfolio CI